Long-term Protection Against Herpes Zoster by the Adjuvanted Recombinant Zoster Vaccine: Interim Efficacy, Immunogenicity, and Safety Results up to 10 Years After Initial Vaccination
Ana Strezova, Javier Díez‐Domingo, Kamal Al Shawafi, Juan Carlos Tinoco, Meng Shi, Paola Pirrotta, Agnes Mwakingwe-Omari, Zoster-049 Study Group, Michael A. Adams, Anitta Ahonen, Charles P. Andrews, Eugene Athan, Jose-Fernando Barba-Gómez, Piero Barbanti, Elisabeth Barberan, Alain Baty, Niklas Bengtsson, Juergen Berger-Roscher, Katarina Berndtsson Blom, Jean Beytout, Loïc Boucher, Céline Boutry, Alain Boye, François Brault, Laurie Breger, Carles Brotons Cuixart, Covadonga Caso, Christine Cerna, Huey‐Shinn Cheng, Hee Jin Cheong, Eun Ju Choo, Clóvis Cunha, Anthony L. Cunningham, Dan Curiac, Benoit Daguzan, Antje Dahmen, Susan Datta, Maria Giuseppina Desole, Emmanuel Di Paolo, Marc Dionne, Petr Dítě, Jan Dutz, John Earl, Tamara Eckermann, William Ellison, Jurij Eremenko, Meral Esen, Takashi Eto, Xavier Farrés Fabré, Cecil Farrington, Murdo Ferguson, Pierre André Ferrand, Matthew Finneran, David Francyk, Marshall Freedman, George Freeman, Antônio Tarcísio Freire, Péter Gál, Jean-Sebastien Gauthier, Beatrice Gerlach, Wayne Ghesquière, Iris Gorfinkel, Christine Grigat, Josef Großkopf, Mónika Inés Hamann, Pascal Hanrion, Paul Hartley, Andrew Hastie, Ken Heaton, Agnes Himpel-Boenninghoff, Thomas Horacek, David S.C. Hui, Yieng Huong, Shinn‐Jang Hwang, Giancarlo Icardi, Gabriele Illies, Junya Irimajiri, Wilson Jacob, Alen Jambrecina, Thiago Junqueira Avelino‐Silva, George Kalema, Hyo Youl Kim, Christiane Klein, Uwe Kleinecke, Hans-Joachim Koenig, Satu Kokko, Pavel Kosina, Susanna Koski, Pekka Koskinen, Maximilian Kropp, Rie Kuroki, Outi Laajalahti, Pierre Lachance, Jacob Lee, Jin Soo Lee, Peter Levins, Robert Lipetz, Bo Liu, Chiu-Shong Liu, Martin Lundvall
Abstract
Approximately 10 years after vaccination with the recombinant zoster vaccine (RZV), an interim analysis of this follow-up study of the ZOE-50/70 trials demonstrated that efficacy against herpes zoster remained high. Moreover, the safety profile remained clinically acceptable, suggesting that the clinical benefit of the RZV in ≥50-year-olds is sustained up to 10 years.